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1. Introduction
The success rate of acute lymphoblastic leukemia (ALL) therapy has gradually increased over
the past decades. With more than 80% long-term survivors, treatment of ALL in children is
undoubtedly one of the great success stories of innovative study-controlled modern medicine
[1]. Attempts to boost cure rates for those who do not respond to therapy or relapse with more
intense chemotherapy including allogeneic hematopoietic stem cell transplantation have
further improved the outcome of patients, particularly for prognostic unfavorable subgroups
[2]. However, intensification of treatment can substantially increase morbidity, the risk for life-
threatening sequelae and mortality [1].
Several studies address this important issue and report on the emergence of fungi. A retro‐
spective review of ~ 5.600 patients who underwent hematopoietic stem cell transplantation at
the Fred Hutchinson Cancer Research Center (Seattle) from 1985 to 1999 reports a constant
increase of 3.5% in the one-year cumulative incidence of probable and proven invasive fungal
infections [3]. Investigation of autopsies, skin, and lung biopsies, and bronchoalveolar lavage
fluid analyses reveal that non-fumigatus Aspergillus species, such as Fusarium and Zygomy‐
cetes have increased, especially in patients, who have received multiple transplants. These
observations are particular worrisome given the increasing importance of amphothericin-B
resistant organisms, resulting in a very poor one-year survival rate of ~ 20% [4]. For those who
do survive, length of hospital stay and total hospital charges are increased, compared with
immunocompromised patients without fungal infection [5].
Despite much effort has been taken to improve therapeutic treatments and strategies, there
still remains much uncertainty and controversy regarding the best method to diagnose,
prevent and treat fungal infections [6]. Practicing physicians approach this uncertainty by
treating suspected infections empirically. However, researchers that conduct clinical trials tend
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to accept only cases in which the diagnosis is certain in order to improve clarity and uniformity
of clinical trials. Therefore, members of the European Organization for Research and Treatment
of Cancer / Invasive Fungal Infection Study Group (EORTC) and the National Institute of
Allergy and Infectious Disease (NIAID) Mycoses Study Group (MSG) formed a consensus
study group to define standard definitions of invasive fungal infections for clinical research
[7]. Practice guidelines are intended to limit practice variations towards movements such as
evidence-based medicine and are primarily suggested by the European Conference of
Infections in Leukemia (ECIL; http://www.ebmt.org/Contents/Resources/Library/ ECIL/
Pages/ECIL.aspx). For the clinical purpose there is still a need to develop more effective
prevention and treatment strategies. Such strategies may rely on newer antifungal agents that
are active against amphothericin B resistant moulds and are well tolerated. Because of limited
number of affected patients, multicenter collaborative trials are required.
This case-based review examines the current literature to explore basic concepts on epidemi‐
ology, diagnosis and treatment of invasive fungal infections in ALL patients. A case report will
be used to illustrate these specific issues.
2. Methods
A systematic review of the literature for an explicit identification of major problems related to
the heterogeneity of patients with acute lymphoblastic leukemia who have invasive fungal
infections was undertaken. Pneumocystis infections were not considered. In brief, the abstracts
of 711 articles published from 1985 through 2012 were screened. Of these, 41 articles were
finally selected because these report clinical research on patients with ALL who also had deep-
tissue fungal infections. The minimum diagnostic criteria used to include patients in the study
were extracted from definitions devised by the investigators. Likewise, the criteria used to
express different degrees of diagnostic probability were summarized, as were the terms most
often used to express these levels of uncertainty.
3. Case study: A sixteen-year old patient with Ph+ ALL
A sixteen-year old adolescent was referred to the outpatient oncologic clinic with suspicion of
a proliferative disease of the hematopoietic system. Two weeks prior the admission, the patient
suffered from sub febrile temperatures and fatigue. At the time of the visit to the general
physician scarlet was ruled out and the patient discharged. At admission, the patient’s general
condition was slightly deteriorated; his physical examination revealed petechial rash over the
extremities, pallor and hepatosplenomegaly. Laboratory findings showed ALL with a positive
BCR/ABL result and an absolute count of 398.000 blasts per µL. He was subjected to treatment
with the ALL BFM 2000 program for high-risk patients. He responded well to chemotherapy
and achieved complete morphological remission on day ten of treatment. Following day
fifteen, the tyrosine-kinase inhibitor Imatinib Mesylate was added to the standard treatment.
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On the  thirtieth  day  of  induction  chemotherapy  the  patient  developed  fever  of  39.2°C.
Physical  examination  was  unremarkable.  The  laboratory  tests  showed leucopenia  (0.5  x
109/L)  with  an  absolute  neutrophilic  count  of  19/µL,  but  no  elevation  of  inflammatory
proteins (CRP <0.06 mg/dL).
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Figure 1. Time course of diagnosis and treatment of fungal infection in a Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph+ALL) patient. Fungal infection was suspected by a chest X-ray on day thirty four of induc‐
tion chemotherapy for Ph+ ALL. Prophylactic treatment with Fluconazole was switched to pre-emptive therapy with
liposomal Amphothericin. Five days later histology of the fungal mass obtained by computed tomography (CT)-guided
percutaneous biopsy confirmed the diagnosis of invasive mould infection. Culture revealed Aspergillus flavus, suscep‐
tible to Voriconazole.
Empirical antibiotic regimen was initiated with a carbapenem (Meropenem) and an amino‐
glycoside (Gentamycin). Because of relapsing fever four days after the initiation of antibiotics,
vancomycin was added. Both blood and urine cultures were aseptic.
A chest X-ray showed a distinctive and peculiar mass in the middle of the right lung. Because
the radiological image was ambiguous the diagnostics were extended by a chest CT scan,
which showed a large mass in the right upper lobe, surrounded by a wide zone of ground-
glass attenuation demonstrating the halo sign. On the ground of the radiologic examinations,
fungal infection was suspicioned and pre-emptive antifungal therapy was initiated. Flucona‐
zole, included in the treatment as a prophylactive measure, was replaced by liposomal
Amphothericin administered at a dose of three mg/kg once daily. On the next day CT-guided
biopsy was planned to obtain a definitive diagnosis. Biopsy was performed with only a single
puncture using a 20 G cutting needle. No pneumothorax or hemorrhage was noted after the
procedure. Histological examination yielded dichotomously branching septated hyphae
consistent with Aspergillus species, confirming the diagnosis of invasive fungal infection.
Culture demonstrated a growth of Aspergillus flavus. Antifungal susceptibility testing with
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the agar-based MIC test showed good activity for Voriconazole, Posaconazole and Caspofun‐
gin, but high MIC90 for liposomal Amphothericin.
Accordingly antifungal therapy was switched to Voriconazole (6 mg/kg) for eight weeks
intravenously and then orally until the twelfth week. CT imaging studies that followed
confirmed a gradual recession of the lesion. The patient underwent right sided thoracotomy
with wedge resection of the fungal mass. Histopathology revealed Aspergilloma with
surrounding chronic granulomatous inflammation, fibrosis and sheets of macrophages. Post-
operative course was uneventful and no recurrence of fungal infection over twenty four
months follow up was observed. He underwent allogeneic hematopoietic stem cell transplan‐
tation and has been in complete molecular remission since.
4. Epidemiology
Worldwide surveys evaluating the epidemiology of invasive fungal infections have been
conducted in large center studies in North America [8]. In European countries data is most
commonly derived from single-center reports or regional reports from single countries [8].
Though local epidemiology is a cornerstone of clinical decision making, efforts are now
undertaken worldwide to start multi-national surveys on fungal infections in order to improve
uniformity of clinical trials.
Until 2 decades ago, infections by Candida were the most common fungal pathogen in patients
treated for ALL. However, with the introduction of Fluconazole as primary antifungal
prophylaxis and the application of more aggressive treatment protocols, including allogeneic
hematopoietic stem cell transplantation, a notable shift towards the advent of invasive
aspergillosis has been noted [9]. Whereas almost all of the fungal infections were attributable
to candidiasis (11/11) in autopsy studies of the late seventies, mould infections were respon‐
sible for 62% of IFIs (16/26) two decades later [9]. Concordantly, a large multi-centre report
from the SEIFEM-2004 study (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie
Maligne) confirms this trend, indicating, that over half of all fungal infections (346/538) were
caused by moulds, in most cases Aspergillus species (310/346) [10]. Most importantly, such
infections have become a prime cause of death in patients with hematologic malignancies. The
IFI-attributable mortality rate was 39% (209/538). The highest IFI-attributable mortality rates
were associated with zygomycosis (64%) followed by fusariosis (53%), aspergillosis (42%), and
candidemia (33%) [10].
Along with the increased incidence of mould infections caused by Aspergillus species, other
emerging mould opportunistics, such as Zygomycetes and Fusarium species, have progres‐
sively been noted; interestingly, frequency varies by geographical location [8]. Another trend
in changing the face of epidemiology is that infections caused by non-albicans Candida species
(e.g. Candida glabrata, C. krusei, C. tropicalis, C. parapsilosis) have steadily increased,
particularly in patients with ALL [11].
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Figure 2. Pathogenic fungi that cause disease in acute lymphoblastic leukemia (ALL) Patients. A schematic classifica‐
tion depending on phylogenetic properties of fungal pathogens encountered in ALL patients is presented.
Yeast like pathogens enter the body via the gut or skin and mostly follow the pattern of
fungemia and disseminated infection known from Candida species. Rarely the central nervous
system, cardiovascular system or other tissues represent sites of dissemination [12].
Besides invasive infections of the skin and subcutaneous tissues, moulds involve, as airborne
pathogens, the sino-pulmonary tract; the emerging opportunistic moulds have a higher
propensity for dissemination, in particular into the central nervous system. Because of the lack
of specific clinical, radiographic and histological features and the absence of diagnostic
surrogate markers in blood, the diagnosis depends on the identification of the organism by
means of culture based methods [12].
5. Diagnostics
In general, diagnostic testing should begin with non-invasive methods and only approach
invasive steps if needed. Diagnostic options include conventional or high-resolution CT (this
has less radiation exposure and was performed in this case report), positron emission tomog‐
raphy (PET), magnetic resonance imaging (MRI), GM assay, 1,3-ß-D-Glucan test, Polymerase
chain reaction (PCR), bronchoalveolar lavage, blood culture and tissue biopsy. At this time,
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MRI and PET are more research-oriented than commonly used clinical approaches. The utility
of standard blood cultures is limited because of a high percentage of false-negative results,
particularly in patients with disseminated aspergillosis. Of the listed options, the GM and 1,3-
ß-D-Glucan serum assay, PCR and the CT scan will be described in detail.
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Figure 3. Simplified view of antifungal strategy in acute lymphoblastic leukemia (ALL) patients. Clinical practice (not
EORTC criteria) in the management of IFIs depends on the population at risk (e.g. genetics, clinical), availability/value
of diagnostic tests and availability/effectiveness of antifungal drugs. HR-ALL: high risk – acute lymphoblastic leukemia;
SCT: stem cell transplantation; GM: Galactomannan; CT: computed tomography.
5.1. Galactomannan (GM)
GM testing with the Platelia Aspergillus Enzyme Immunoassay (EIA; Biorad Laboratories,
Redmond, WA) has been approved by the U.S. Food and Drug Administration (FDA) for
Aspergillus diagnostics and is included as a mycological criterion in the revised definitions of
invasive fungal disease from the EORTC/MSG consensus group [6]. The test is based on
detection of a component of the Aspergillus cell wall, Galactomannan (GM), which is released
in the surrounding environment by growing Aspergillus species. Concentration of serum GM
correlates with fungal burden in animals with experimental pulmonary aspergillosis – and,
according to the 2011 ECIL clinical practice guidelines may be considered as surrogate marker
for detection of invasive aspergillosis (http://www.ebmt.org/Contents/Resources/Library/
ECIL/Pages/ECIL.aspx). Recent data suggest that sequential measuring of GM serum levels
may be used for therapeutic monitoring in children and adults with pulmonary aspergillosis.
The guidelines from the Infections Disease Society of America (IDSA) state, that duration of
antifungal therapy must not only rely on disappearance of GM levels, but also on resolution
of clinical and radiological findings [13].
The GM EIA has been most studied in hematologic malignancy and bone marrow transplan‐
tation populations. Both the specificity and sensitivity of the GM EIA for invasive aspergillosis
are high for infected, neutropenic adult patients from these populations. Comparison of 5
studies which use EORTC/MSG criteria and give adequate information for individual patients
with results of a formal meta-analysis, indicate sensitivity, specificity of 76% to 73%, 86% to
90% in children and adults respectively [14]. Controversy of GM testing exists about the
interpretation of the assay cutoff level (0.5, 1.0), which was originally set at 1.5 and was applied
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in Europe but which was lowered to 0.5 after review by the FDA. Studies have shown that
using an index cutoff for positivity of 0.5 versus greater indices substantially increases
sensitivity, with only minimal loss in specificity [15]. Factors, which increase false positivity
and influence the specificity of the assay, include a low level of cut-off (<0.5), colonization with
Bifidobacterium bifidum in the intestinal flora, which mimics the epitope recognized by the
EB-A2 in the enzyme-linked immunosorbent assay kit [16] and invasive infections with other
fungi, such as Penicillium spp., histoplasmosis, and blastomycosis [13]. Moreover, cross-
reactivity of the assay has been shown with the use of piperacillin/ tazobactam or amoxicillin/
clavulanate antibiotic therapy and in infants with the nutrition of milk-based formulas [17].
The IDSA guidelines currently recommend using the GM EIA in conjunction with CT scans
for early, noninvasive diagnosis of invasive aspergillosis in high-risk patients [13]. The test
should be performed serially, at least twice per week through the periods of highest risk,
whether the periods involve neutropenia or active GVHD [13].
When GM in serum is used for screening for invasive mold infection in children with hema‐
tological malignancies/undergoing HSCT, data should be interpreted with caution, since the
assay has a number of limitations in the sensitivity and specificity profile. Prospective
monitoring of GM in serum every three to four days in children at high risk for IFD is reason‐
able for early diagnosis of invasive aspergillosis. Although the optimal cut-off value of GM in
the serum of children is not well defined, published data support the use of a threshold of an
optical density index 0.5 (http://www.ebmt.org/Contents/Resources/Library/ ECIL/Pages/
ECIL.aspx).
5.2. 1,3-ß-D Glucan
1,3-ß-D Glucan (BG) is a fungal cell wall component circulating in the blood of patients with
invasive aspergillosis, candidemia, but also Fusarium, Trichosporum, Saccharomyces, and
Pneumocystis jirovecii. Moreover, BG is also detected in patients with infections due to bacteria
such as Streptococcus pneumoniae, Pseudomonas aeruginosa and in healthy individuals.
However, BG is absent in patients with cryptococcosis and zygomycosis [18]. Antibiotics such
as cefepime, piperacillin/tazobactam or meropenem may cause positive BG levels. Investiga‐
tions using different BG assays in 2979 patients (594 with proven or probable IFI) have reported
a pooled sensitivity of 76.8% and specificity of 85.3% [19]. Differences in study design (popu‐
lation studies versus case-control, variation in the number of proven or probable IFIs, propor‐
tions of patients with candidemia and aspergillosis, case-mix of neutropenic and non-
neutropenic patients, and previous antifungal prophylaxis) highlight the need for further
investigations. In children, data is very limited: elevated levels of BG were reported in a case-
control study of only four children with IFI (3 patients with candidemia, one patient probable
aspergillosis) [20].
The Fungitell assay (Associates of Cape Cod) for detection of 1,3-ß-D Glucan is approved by
the FDA for the diagnosis of invasive mycoses, including aspergillosis [13] and is included as
mycological criterion in the revised definitions of invasive fungal disease from the
EORTC/MSG consensus group [6]. Unfortunately, there is no recommendation from ECIL or
IDSA for clinical practice. However, BG testing in adults is considered as having good
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diagnostic accuracy for early diagnosis of IFD; in children, data are too limited to make any
recommendations (http://www.ebmt.org/Contents/Resources/Library/ ECIL/Pages/
ECIL.aspx).
5.3. PCR
Detection of antifungal DNA has been advocated as a promising, rapid and more sensitive
diagnostic tool, but false-positive results can occur, and a standardized commercial method is
not yet available. Several PCR assays to detect fungal DNA have been described, but most
have shown that the global performance was too low to be of clinical interest. Different
situations have been reported: PCR either has high sensitivity and NPV, while specificity and
PPV is low, or, conversely, high specificity and PPV with low sensitivity and NPV [21-24].
These discrepancies can be due to the different technical approaches used. Indeed, a major
difference is the type of PCR method used in these studies, i.e., nested PCR, PCR–enzyme-
linked immunosorbent assay, or RT-PCR [22;24]. Also, the superiority of large serum volumes
(> 1 ml) in comparison with conventional serum samples (100 µl to 200 µl) has clearly been
shown [23]. In view of changing epidemiology a panfungal PCR might be advantageous to
permit the detection of a wide range of fungal pathogens. Its sensitivity of 96%, negative
predictive values of 98%, whereas the specificity and positive predictive value were 77% and
62%, respectively is far superior to single PCR measurements [25].
In summary, despite ISDA and ECIL do not give any recommendations, combining non-
culture based diagnostics is an important research direction that may improve the overall
predictive value of these systems [26].
5.4. Chest CT scan
Systematic chest CT scan allows early diagnosis of invasive pulmonary aspergillosis, is more
sensitive and specific than traditional chest radiographs and is a clinical criterion in the revised
definitions of invasive fungal disease from the EORTC/MSG consensus group. Characteristic
findings consist of nodules surrounded by the ‘halo sign’, an area of haziness or ground-glass
opacity, or pleura-based, wedge-shaped areas of consolidation [27]. These findings correspond
to areas of hemorrhagic infarcts. In severely neutropenic patients, the halo sign is highly
suggestive of angioinvasive aspergillosis. However, a similar appearance has been described
in a number of other conditions, including infections with herpes virus or cytomegalovirus,
Kaposi sarcoma, Wegener granulomatosis, and bronchiolitis obliterans organizing pneumonia
[12]. The air crescent sign, a crescent-shaped area of radiolucency in a region of nodular opacity,
is usually seen during convalescence in angioinvasive aspergillosis (i.e., 2–3 weeks after
initiation of treatment and concomitant with resolution of the neutropenia) [28]. Of note, some
studies suggest that cavitation and the air-crescent sign are more likely to be observed in adults,
and may frequently be absent from CT scans obtained from young children with pulmonary
invasive aspergillosis [29]. When obtaining serial CT scans, it is also important to realize that
irrespective of antifungal therapy, the pattern is characterized by an initial rise in number and
size of lesions, followed by a plateau in lesion size, and gradual reduction [12]. Moreover, is
time until complete radiologic remission and outcome independent of initial or maximum
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lesion size and number in patients with invasive pulmonary aspergillosis [30]. The appearance
of cavities on serial CT scans (frequently accompanied by the appearance of the air-crescent
sign as neutropenia resolves) may be indicative of patient recovery. Similarly, if antifungal
therapy is initiated and subsequent scans show an increase in the number or size of lesions,
this is more likely a reflection of the typical progression of disease rather than failed therapy.
According to the ECIL recommendations, in high-risk patients with persistent febrile neutro‐
penia that persists beyond 96 hours or with focal clinical findings, imaging studies (e.g., CT-
scan of the lung or adequate imaging of the symptomatic region) should be performed. Further
diagnostic work-up (e.g., BAL, biopsy) should be considered and mold-active antifungal
treatment should be initiated.
6. Treatment
Antifungal strategies include prophylaxis, empiric antifungal therapy, pre-emptive antifungal
therapy and treatment of established invasive fungal infection (Figure 3). For individual
patient populations, each strategy needs to consider the patients risk, the local epidemiology,
the availability of diagnostic tools and the availability and effectiveness of antifungal agents.
Last, but not least a cost – benefit analysis (i.e. toxicity, financial aspects) is mandatory. For the
purpose of this textbook spectrum, potency, mode of action, and clinical indication of anti‐
fungal agents will be discussed.
6.1. Amphotericin B
Amphotericin deoxycholate (DAMB) and its lipid formulations, including amphotericin B
colloidal dispersion (ABCD), amphotericin B lipid complex (ABLC), and liposomal ampho‐
tericin B (LAMB,) have a wide range of activity against most fungal pathogens. Only Asper‐
gillus terreus and Fusarium species are less susceptible (Table 1.) [31].
In comparison to DAMB, nephrotoxicity is rarely seen with the use of the lipid formula‐
tions; infusion-related reactions, such as fever, chills and rigor are substantially less frequent
with LAMB. Mild increases in bilirubin and alkaline phosphatase are associated with all
three lipid formulations, elevation of transaminases with LAMB only. Currently, DAMB is
licensed for neonatal invasive candidiasis and induction therapy for cryptococcal meningi‐
tis; LAMB is approved as first line empirical treatment of suspected invasive aspergillosis
and  candidiasis;  ABCD  is  licensed  for  second-line  treatment  of  patients  with  invasive
aspergillosis,  and ABLC for  second-line  treatment  of  patients  with  invasive  Candida or
Aspergillus infections [34].
The recommended therapeutic dosages are 0.7 to 1.0 mg/kg/day for DAMB, 3–4 mg/kg/day
for ABCD, 5 mg/kg/day for ABLC, and 3 (to 5) mg/kg/day for LAMB, respectively. The
available evidence does not suggest pharmacokinetic differences of LAMB between adults and
children including preterm and newborn infants [33].
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6.2. Fluconazole
Fluconazole has a very narrow fungal susceptibility against Candida species (Candida glabrata
and krusei have a high MIC index) and lacks activity against Aspergillus species and zygo‐
mycetes (Table 1.). Fluconazole is not metabolized and mainly renally excreted, and drug levels
correlate with strictly with renal function [33]. It is licensed for prophylactic use in patients at
risk for IFIs and for targeted treatment of candidiasis. For pediatric patients (they show a more
rapid excretion and shorter half-life), the recommended dosage is higher than for adults, 8 to
12 mg/kg/day versus 5 mg/kg/day, respectively [34].
6.3. Itraconazole
The compound is active against most Candida and Aspergillus species, but the susceptibility
against Candida glabrata and C. krusei is limited (Table 1). There is no activity against
zygomycetes. The pharmacokinetics is characterized by inter-individual variability of gastro‐
intestinal absorption and hepatic metabolism [35]. Accordingly, measurement of drug levels
is necessary and results of meta-analysis suggest that the trough plasma level should be higher
than 0.5 µg / mL [36]. Concerns have arisen on the interaction with drugs such as vincristine
and cyclosporine, which are major components of both induction ALL therapy and prevention
of GvHD in ALL transplanted patients. Moreover, 10% of patients experience gastrointestinal
adverse effects, such as nausea and diarrhea, which limits its acceptance [34]. According to the
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Clinical Epidemiology of Acute Lymphoblastic Leukemia - From the Molecules to the Clinic326
ECIL and IDSA guidelines, Itraconazole should be used as second-line therapy in the preven‐
tion of IFIs.
6.4. Voriconazole
Voriconazole has similar activity as Itraconazole and is active against most Candida and
Aspergillus species, but not zygomycetes, Candida glabrata and C. krusei (Table 1.). The
effectiveness of this compound has been demonstrated in large clinical trials in both adults
and children, and has led to its approval for empirical and pre-emptive antifungal therapy [31].
Because of its wide use, breakthrough infections with zygomycetes have been reported [37].
Additionally, breakthrough infections with susceptible strains have been noted in patients
with low plasma levels, necessitating the monitoring of through plasma levels [38]. In children,
Voriconazole is more rapidly metabolized, suggesting a higher dosage of 7-8 mg/kg/b.i.d. than
in adults (4-5 mg/kg/b.i.d.) [33]. Relevant side effects of Voriconazole include elevations of
liver enzymes, visual disturbances and photosensitivity skin reactions, particularly if com‐
bined with nucleoside analoga, which are commonly used in the treatment of ALL. In addition,
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Candida albicans + (+) + + + + +
C. parapsilosis + + + + + +/- +/-
C. lusitaniae -/+ + + + + + +
C. tropicalis + -/+ + + + + +
C. glabrata + - -/+ + -/+ + +
C. krusei + - -/+ + -/+ + +
Asp. fumigatus + - + + + + +
Asp. flavus (+) - + + + + +
Asp. terreus - - + + + + +
Asp. niger + - (+) + (+) + +
Zygomycetes + - - (+) - - -
Fusarium spp. (+) - - - - - -
+ = high activity rate; (+) = little reduced activity rate; -/+ = higher resistant rates in some areas; - = mostly resistant
[11;32;33].C.: Candida; Asp.: Aspergillus; spp.: species.
Table 1. Susceptibility of important fungal pathogens against some common antifungal agents.
Invasive Fungal Infections in ALL Patients
http://dx.doi.org/10.5772/54990
327
the interaction of Voriconazole with a number of drugs (e.g. Vincristine, Cyclosporine A, and
Omeprazole) has to be considered [33].
6.5. Posaconazole
This compound has a potent and broad-spectrum activity against most clinically important
fungal infections, including zygomycetes, distinguishing it from the other azoles [33]. Accord‐
ing to the ECIL/ IDSA guidelines it is recommended as second-line treatment of aspergillosis,
fusariosis, chromoblastomycosis and coccidioidomycosis. In addition, Posaconazole is
approved for prophylaxis in high-risk patients older than 13 years of age with ALL and in
hematopoietic stem cell transplant patients with graft-versus-host disease [31;39]. The dosage
for prophylaxis is 200 mg three times daily, for salvage treatment the dose is increased to 400
mg two times daily. Similar to Voriconazole, interference with cytochrome P450 dependent
metabolites (e.g. Cyclosporine) need to be considered [34].
6.6. Caspofungin
Caspofungin is active against Candida spp. and Aspergillus spp., but resistant against
Cryptococcus species and zygomycetes (Table 1.). It is licensed for adult and pediatric patients,
including neonates, for empirical antifungal therapy in persistently febrile neutropenic
patients, for second-line pre-emptive therapy of suspected aspergillosis and for primary
therapy in non-neutropenic patients with invasive Candida infections. The recommended dose
regimen in adults consists of a single 70-mg loading dose on day 1, followed by 50 mg daily
thereafter [34]. A dosage of 1 mg/kg for children has been suggested [31]. A favorable safety
profile has been described, the most common drug-related adverse events were fever,
increased ALT, and rash; few events were serious or required treatment discontinuation [40].
6.7. Micafungin
Micafungin was recently licensed for neonates, children and adults for prophylaxis and
treatment of invasive candidiasis in patients with prolonged neutropenia and after hemato‐
poietic stem cell transplantation [41]. The spectrum of activity is similar to that of Caspofungin
(Table 1). The recommended dosage is 100 mg/day for invasive candidiasis (≤40 kg body
weight: 2 mg/kg) with the option of dose escalation to 200 mg/day or 4 mg/kg/day; and 50 mg/
day (≤40 kg: 1 mg/kg) in the preventive indication [34]. The most frequent adverse events
include vomiting, high fever, diarrhea, nausea, and hypokalemia [41].
7. Conclusion
Although various guidelines on antifungal management have been published, we suggest
using a simple approach, which is guided by local factors, such as the pattern of resistance and
the availability of diagnostic tools. As newer strategies might soon be implemented, we are
unable to assess the efficacy of our approach to date. Our report underlines that many
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questions regarding antifungal treatment have to be addressed in future studies, such as the
duration of treatment or the benefit of costly combination antifungal therapy.
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